多替拉韦联合达芦那韦/考比司他双药方案在经治HIV感染者中的长期持久性
BACKGROUND: A dolutegravir plus darunavir/cobicistat regimen has been used as a simplified option in heavily treatment-experienced people with HIV (PWH). We report on long-term results of this regimen as assessed by treatment discontinuation (TD) for any reason.…
要点
- 7年治疗中断概率35.0%,中位随访4年,方案在重度经治人群中显示持久性
- 基线HIV RNA>50 copies/mL者中断风险升高(HR=2.14)
- 存在PI或INSTI耐药突变者中断风险显著升高(HR=5.48)
核心结论
- 多替拉韦联合达芦那韦/考比司他是重度经治HIV感染者的持久组合。
- 转换时存在病毒血症者更可能中断治疗,但多数中断原因非病毒学失败。
研究设计与样本
- 主要终点为任何原因的治疗中断率,采用Kaplan-Meier生存分析和多重Cox回归评估中断概率。
主要发现
- 基线63.6%的个体HIV RNA<50 copies/mL;NRTI、NNRTI、PI和INSTI原发耐药相关突变记录率分别为88.0%、70.0%、24.5%和6.6%。
- 中位随访4年(IQR 3.3-6.9),治疗1、2、3、4、5、6和7年后中断概率分别为8.3%、13.0%、18.0%、22.0%、25.0%、30.0%和35.0%。
- 83例发生治疗中断,主要原因包括死亡(n=20)、简化治疗(n=13)、毒性(n=11)、不耐受(n=9)、药物相互作用(n=10)和病毒学失败(n=7)。
- Cox回归显示,基线HIV RNA>50 copies/mL(HR=2.14,95%CI 1.20-3.81;P=0.01)和存在PI或INSTI耐药突变(HR=5.48,95%CI 2.42-12.4;P<0.001)与更高的治疗中断概率相关。
临床怎么用
- 多替拉韦联合达芦那韦/考比司他可作为重度经治HIV感染者的简化治疗选项,长期持久性数据支持其应用。
- 转换时病毒血症阳性或存在PI/INSTI耐药突变者治疗中断风险较高,需加强监测。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A dolutegravir plus darunavir/cobicistat regimen has been used as a simplified option in heavily treatment-experienced people with HIV (PWH). We report on long-term results of this regimen as assessed by treatment discontinuation (TD) for any reason. METHODS: This was a retrospective, observational, multicentre study. PWH started on dolutegravir plus darunavir/cobicistat from 1 December 2015 to 31 December 2022 were included. The primary endpoint was the rate of TD for any reason. Survival analysis with the Kaplan-Meier estimator was used to assess the probability of TD over time. Multiple Cox regression was used to estimate the probability of TD at 1 year following regimen initiation. RESULTS: Three hundred and twenty-seven subjects were included. At baseline, 63.6% of individuals had HIV RNA of <50 copies/mL. Primary resistance-associated mutations for NRTIs, NNRTIs, PIs and integrase inhibitors were documented in 88.0%, 70.0%, 24.5% and 6.6%, respectively. Median follow-up was 4 years (IQR 3.3-6.9). Probability of TD was 8.3%, 13.0%, 18.0%, 22.0%, 25.0%, 30.0% and 35.0% after 1, 2, 3, 4, 5, 6 and 7 years of treatment, respectively. TD occurred in 83 subjects, largely due to death (n = 20), simplification (n = 13), toxicity (n = 11), intolerance (n = 9), drug interactions (n = 10) and virological failure (n = 7). At Cox regression analysis, factors associated with a higher probability of TD over time were baseline HIV RNA of >50 copies/mL (HR = 2.14, 95% CI 1.20-3.81; P = 0.01) and the presence of PI or integrase strand transfer inhibitor resistance mutations (HR = 5.48, 95% CI 2.42-12.4; P < 0.001). CONCLUSIONS: Dolutegravir plus darunavir/cobicistat is a durable combination in heavily treatment-experienced PWH. Those who were viraemic at the time of switch were more likely to discontinue, although most reasons for TD were other than virological failure.
引用
- Ripamonti D, Comi L, Francavilla A, et al. Long-term durability of dolutegravir plus darunavir/cobicistat dual regimen in highly antiretroviral-experienced people with HIV (DoDaco study). J Antimicrob Chemother. 2025. PMID: 40202851. doi:10.1093/jac/dkaf119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。